{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-027887","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-05-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.034813+00:00","generated_at":"2026-06-25T10:04:58.072233+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"InMed Q3 FY2022 net loss $10.7M; revenue $0.6M from BayMedica; board adds Baldasare","bullets":["Net loss for 9 months ended Mar 31, 2022: $10.7M ($0.81/share) vs $6.9M ($1.11/share) prior year.","BayMedica generated $0.6M revenue from rare cannabinoid sales; gross profit $0.3M.","Cash, cash equivalents and short-term investments $5.9M vs $7.4M at June 30, 2021.","Appointed Bryan Baldasare to Board of Directors; board expanded to six members.","Phase 2 trial of INM-755 for EB continues; pIND for INM-088 glaucoma aligns with FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-027887","json":"https://secwatch.observer/filing/0001213900-22-027887.json","markdown":"https://secwatch.observer/filing/0001213900-22-027887.md","text":"https://secwatch.observer/filing/0001213900-22-027887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022027887/0001213900-22-027887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022027887/ea160171-8k_inmedphar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T10:04:58.072233+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aac27b4558","claim":"Bryan Baldasare was appointed as director at InMed Pharmaceuticals Inc..","evidence_excerpt":"On May 12, 2022, the Board appointed Bryan Baldasare as a director of the Board and concurrently increased the size of the Board to six members, effective as of May 12, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022027887/0001213900-22-027887-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}